Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

Official Title

A Phase III Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Efficacy and Safety of Elafibranor 80 mg on Long-Term Clinical Outcomes in Adult Participants With Primary Biliary Cholangitis (PBC)

Keywords

Primary Biliary Cholangitis (PBC), Cholangitis, Biliary Liver Cirrhosis, Elafibranor, Elafibranor 80 mg

Eligibility

Locations

  • University of California Los Angeles accepting new patients
    Los Angeles California 90404 United States
  • GastroIntestinal BioSciences accepting new patients
    Los Angeles California 90067 United States
  • Cedars-Sinai Medical Center not yet accepting patients
    Los Angeles California 90048 United States
  • Southern California Research Center accepting new patients
    Coronado California 92118 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Ipsen
ID
NCT06016842
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 276 study participants
Last Updated